BMO Capital Remains a Hold on Stryker Corporation

By Jason Carr

In a report issued on July 10, Joanne Wuensch from BMO Capital reiterated a Hold rating on Stryker Corporation (NYSE: SYK), with a price target of $174. The company’s shares closed yesterday at $173.42, close to its 52-week high of $179.84.

According to TipRanks.com, Wuensch is a 5-star analyst with an average return of 10.8% and a 68.9% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Baxter International.

Stryker Corporation has an analyst consensus of Moderate Buy, with a price target consensus of $181.75.

See today’s analyst top recommended stocks >>

The company has a one-year high of $179.84 and a one-year low of $137.70. Currently, Stryker Corporation has an average volume of 1.41M.

Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SYK in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stryker Corp. engages in providing medical technology products and services. It operates through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine. The Orthopaedics segment provides reconstructive and trauma implant systems.